FR2397190A1 - Moyen pour l'administration de medicaments a travers la peau - Google Patents

Moyen pour l'administration de medicaments a travers la peau

Info

Publication number
FR2397190A1
FR2397190A1 FR7800015A FR7800015A FR2397190A1 FR 2397190 A1 FR2397190 A1 FR 2397190A1 FR 7800015 A FR7800015 A FR 7800015A FR 7800015 A FR7800015 A FR 7800015A FR 2397190 A1 FR2397190 A1 FR 2397190A1
Authority
FR
France
Prior art keywords
clonidine
administration
skin
drug
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7800015A
Other languages
English (en)
French (fr)
Other versions
FR2397190B1 (cg-RX-API-DMAC10.html
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of FR2397190A1 publication Critical patent/FR2397190A1/fr
Application granted granted Critical
Publication of FR2397190B1 publication Critical patent/FR2397190B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2323/00—Polyalkenes
    • B32B2323/10—Polypropylene
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2556/00—Patches, e.g. medical patches, repair patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR7800015A 1977-07-12 1978-01-02 Moyen pour l'administration de medicaments a travers la peau Granted FR2397190A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/815,033 US4201211A (en) 1977-07-12 1977-07-12 Therapeutic system for administering clonidine transdermally

Publications (2)

Publication Number Publication Date
FR2397190A1 true FR2397190A1 (fr) 1979-02-09
FR2397190B1 FR2397190B1 (cg-RX-API-DMAC10.html) 1982-10-15

Family

ID=25216676

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7800015A Granted FR2397190A1 (fr) 1977-07-12 1978-01-02 Moyen pour l'administration de medicaments a travers la peau

Country Status (34)

Country Link
US (1) US4201211A (cg-RX-API-DMAC10.html)
JP (1) JPS5420129A (cg-RX-API-DMAC10.html)
AR (1) AR218037A1 (cg-RX-API-DMAC10.html)
AT (1) AT362884B (cg-RX-API-DMAC10.html)
AU (1) AU512328B2 (cg-RX-API-DMAC10.html)
BE (1) BE862585A (cg-RX-API-DMAC10.html)
BG (1) BG29866A3 (cg-RX-API-DMAC10.html)
CA (1) CA1089362A (cg-RX-API-DMAC10.html)
CH (1) CH646876A5 (cg-RX-API-DMAC10.html)
CS (1) CS216917B2 (cg-RX-API-DMAC10.html)
DD (1) DD135566A5 (cg-RX-API-DMAC10.html)
DE (1) DE2755661C2 (cg-RX-API-DMAC10.html)
DK (1) DK159375C (cg-RX-API-DMAC10.html)
ES (2) ES245891Y (cg-RX-API-DMAC10.html)
FI (1) FI772754A7 (cg-RX-API-DMAC10.html)
FR (1) FR2397190A1 (cg-RX-API-DMAC10.html)
GB (1) GB1577259A (cg-RX-API-DMAC10.html)
GR (1) GR61591B (cg-RX-API-DMAC10.html)
HU (1) HU179397B (cg-RX-API-DMAC10.html)
IE (1) IE46069B1 (cg-RX-API-DMAC10.html)
IL (1) IL52839A (cg-RX-API-DMAC10.html)
IT (1) IT1104643B (cg-RX-API-DMAC10.html)
LU (1) LU78845A1 (cg-RX-API-DMAC10.html)
NL (1) NL189800C (cg-RX-API-DMAC10.html)
NO (1) NO772955L (cg-RX-API-DMAC10.html)
NZ (1) NZ185000A (cg-RX-API-DMAC10.html)
PH (1) PH16059A (cg-RX-API-DMAC10.html)
PL (1) PL113984B1 (cg-RX-API-DMAC10.html)
PT (1) PT67128B (cg-RX-API-DMAC10.html)
RO (1) RO75336A (cg-RX-API-DMAC10.html)
SE (1) SE7709731L (cg-RX-API-DMAC10.html)
SU (1) SU1005650A3 (cg-RX-API-DMAC10.html)
YU (1) YU41594B (cg-RX-API-DMAC10.html)
ZA (1) ZA775848B (cg-RX-API-DMAC10.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0020905A1 (de) * 1979-05-21 1981-01-07 C.H. Boehringer Sohn Pharmazeutische Zubereitung in Form eines Polyacrylatfilmes und deren Herstellung
EP0232580A3 (en) * 1986-01-13 1989-06-21 Alza Corporation Transdermal system ii
EP0267051A3 (en) * 1986-11-07 1990-10-03 Moleculon Inc. Transdermal administration of amines
EP0345884A3 (en) * 1988-06-06 1990-12-05 The Dow Chemical Company Coextruded synthetic resin structures and a process for their manufacture
WO1997004818A3 (de) * 1995-07-29 1997-03-13 Lohmann Therapie Syst Lts Transdermales therapeutisches system zur abgabe von wirkstoffen über die haut an den menschlichen körper

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57134413A (en) * 1981-02-14 1982-08-19 Nitto Electric Ind Co Ltd Percutaneous absorbable drug and product containing the same
JPS6059207B2 (ja) * 1981-03-13 1985-12-24 日東電工株式会社 複合製剤の製法
JPS57150503U (cg-RX-API-DMAC10.html) * 1981-03-17 1982-09-21
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
GB2105990B (en) * 1981-08-27 1985-06-19 Nitto Electric Ind Co Adhesive skin patches
US5310559A (en) * 1982-09-01 1994-05-10 Hercon Laboratories Corporation Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
JPS5984813A (ja) * 1982-11-08 1984-05-16 Sekisui Chem Co Ltd 薬剤徐放性製剤
JPS5984817A (ja) * 1982-11-08 1984-05-16 Sekisui Chem Co Ltd 薬剤徐放性製剤
JPS5984814A (ja) * 1982-11-08 1984-05-16 Sekisui Chem Co Ltd 薬剤徐放性製剤
GB2133284A (en) * 1983-01-07 1984-07-25 English Grains Limited Resilient pharmaceutical unit for treating mouth ulcers
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
FR2548021B1 (fr) * 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
DE3344691A1 (de) * 1983-12-10 1985-06-20 Bayer Ag, 5090 Leverkusen Wirkstoffabgasesysteme
DE3347277A1 (de) * 1983-12-28 1985-07-11 Bayer Ag, 5090 Leverkusen Wirkstoffabgabesysteme
JPS60185713A (ja) * 1984-03-05 1985-09-21 Nitto Electric Ind Co Ltd 経皮吸収性製剤及びその製法
EP0156080B2 (en) * 1984-03-05 1993-10-20 Nitto Denko Corporation Percutaneous absorption type adhesive pharmaceutical preparation
DE3409079A1 (de) * 1984-03-13 1985-09-19 Bayer Ag, 5090 Leverkusen Medizinische pflaster
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4655768A (en) * 1984-07-06 1987-04-07 Avery International Corporation Bandage for sustained delivery of drugs
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
EP0186019B1 (de) * 1984-12-22 1993-10-06 Schwarz Pharma Ag Wirkstoffpflaster
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
DE3518707A1 (de) * 1985-05-24 1986-11-27 Beiersdorf Ag, 2000 Hamburg Nitro-pflaster
EP0252076A1 (en) * 1985-12-12 1988-01-13 Flexcon Company, Inc. Transdermal methods and adhesives
US4765974A (en) * 1985-12-24 1988-08-23 Nitto Electric Industrial Co., Ltd. Preparation for percutaneous administration
JPS63502282A (ja) * 1986-01-31 1988-09-01 ホイットビ−・リサ−チ・インコ−ポレ−テッド １−置換アザシクロアルカン類より成る組成物とその用法
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
ES2028074T3 (es) * 1986-06-13 1992-07-01 Alza Corporation Activacion por humedad de un sistema de suministro transdermico de farmacos.
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5227157A (en) * 1986-10-14 1993-07-13 Board Of Regents, The University Of Texas System Delivery of therapeutic agents
US4917688A (en) * 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
US4830856A (en) * 1987-01-27 1989-05-16 Peppers James M Chelation product
US4879275A (en) * 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US4920101A (en) * 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
JPH02149514A (ja) * 1988-04-06 1990-06-08 Nitto Denko Corp 医薬部材
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5241925A (en) * 1988-12-27 1993-09-07 Dermamed Apparatus and techniques for administering veterinary medicaments
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5324521A (en) * 1989-12-18 1994-06-28 Dermamed Systems for transdermal administration of medicaments
US5447947A (en) * 1990-02-26 1995-09-05 Arc 1 Compositions and methods of treatment of sympathetically maintained pain
US5070084A (en) * 1990-02-26 1991-12-03 Campbell James N Treatment of sympathetically maintained pain
US6559186B1 (en) 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
US5508038A (en) * 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
US5402777A (en) * 1991-06-28 1995-04-04 Alza Corporation Methods and devices for facilitated non-invasive oxygen monitoring
IT1251469B (it) * 1991-07-15 1995-05-15 Zambon Spa Sistema terapeutico transdermale per la somministrazione di farmaci ad attivita' broncodilatante.
AU660336B2 (en) * 1991-10-18 1995-06-22 Alza Corporation Device for the transdermal administration of melatonin
ATE185694T1 (de) * 1992-05-13 1999-11-15 Alza Corp Oxybutynin zur transdermalen verabreichung
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US5451407A (en) * 1993-06-21 1995-09-19 Alza Corporation Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug
WO1995001167A2 (en) * 1993-06-25 1995-01-12 Alza Corporation Incorporating poly-n-vinyl amide in a transdermal system
CA2167526A1 (en) * 1993-09-29 1995-04-06 Lina Tormen Taskovich Monoglyceride/lactate ester permeation enhancer
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
CN1078460C (zh) * 1995-03-23 2002-01-30 北京三九克莱斯瑞控释药业有限公司 程控型透皮贴剂
US5662928A (en) * 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
US6572879B1 (en) 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US6238700B1 (en) 1995-12-01 2001-05-29 Alza Corporation Method for preventing crystal formation in a dispersion of a liquid in a matrix
EP0863751B1 (en) 1995-12-01 2001-10-24 Alza Corporation Improved method for preventing crystal formation in a dispersion of a liquid in a matrix
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US5869089A (en) * 1996-03-21 1999-02-09 China-America Technology Corp. (Ctc) Manufacturing method of programmable transdermal therapeutic system
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
GB9711032D0 (en) * 1997-05-30 1997-07-23 Johnson Matthey Plc Compound as a stimulant for the central nervous system
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6660295B2 (en) 1997-09-30 2003-12-09 Alza Corporation Transdermal drug delivery device package with improved drug stability
KR100576583B1 (ko) 1997-12-22 2006-05-04 알자 코포레이션 서방성 약물 송달 장치용 속도 조절막
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
US6348210B1 (en) 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
PL195871B1 (pl) 1998-12-18 2007-11-30 Alza Corp Urządzenie do przezskórnego dostarczania nikotyny
AU778081B2 (en) * 1999-03-25 2004-11-11 Tepha, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
JP2003508425A (ja) 1999-08-30 2003-03-04 テファ， インコーポレイテッド 洗浄可能な使い捨てポリマー製品
CN100357244C (zh) 2000-02-16 2007-12-26 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
WO2003032983A1 (en) * 2001-06-05 2003-04-24 Ronald Aung-Din Transdermal migraine therapy
US7030159B2 (en) 2001-12-18 2006-04-18 The Brigham And Women's Hospital, Inc. Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
AR033748A1 (es) * 2002-05-15 2004-01-07 Thalas Group Inc Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo
EP2216318B1 (en) * 2002-08-12 2018-10-10 Brigham And Women's Hospital Resolvins: Biotemplates for therapeutic interventions
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
US20040258742A1 (en) * 2003-04-11 2004-12-23 Van Osdol William Woodson Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines
US8034270B2 (en) 2003-05-08 2011-10-11 Tepha, Inc. Polyhydroxyalkanoate medical textiles and fibers
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20060200100A1 (en) * 2003-06-18 2006-09-07 Rosati Coni F Method and apparatus for supplying gas to an area
US7014630B2 (en) * 2003-06-18 2006-03-21 Oxyband Technologies, Inc. Tissue dressing having gas reservoir
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
AU2004257701B2 (en) * 2003-07-08 2007-09-13 Tepha, Inc. Poly-4-hydroxybutyrate matrices for sustained drug delivery
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
JP2007503221A (ja) * 2003-08-22 2007-02-22 テファ， インコーポレイテッド ポリヒドロキシアルカノエート神経再生デバイス
TWI239252B (en) * 2003-12-31 2005-09-11 Ind Tech Res Inst A patch and the manufacturing method of the same
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
WO2005107834A1 (en) * 2004-04-30 2005-11-17 Clawson Burrell E Apparatus and methods for isolating human body areas for localized cooling
US7611628B1 (en) 2004-05-13 2009-11-03 University Of Kentucky Research Foundation Aligned nanotubule membranes
DE602005022197D1 (de) * 2004-08-03 2010-08-19 Tepha Inc Nichtkräuselnde polyhydroxyalkanoatnähte
ATE471146T1 (de) 2004-10-21 2010-07-15 Durect Corp Transdermale verabreichungssysteme
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
EP1845951B1 (en) * 2005-01-28 2010-09-15 Tepha, Inc. Embolization using poly-4-hydroxybutyrate particles
EP1933852B1 (en) * 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
US8026266B2 (en) * 2005-11-08 2011-09-27 Arcion Therapeutics, Inc. Treatment of length dependent neuropathy
US7888422B2 (en) * 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
WO2007061783A1 (en) 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
CN106667918A (zh) 2005-11-28 2017-05-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
DK2026803T3 (da) * 2006-05-16 2012-04-16 Knopp Neurosciences Inc Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
AU2007325628A1 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US7943683B2 (en) * 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20080152709A1 (en) * 2006-12-22 2008-06-26 Drugtech Corporation Clonidine composition and method of use
US20100143270A1 (en) * 2007-02-21 2010-06-10 University Of Louisville Research Foubdation Therapeutic cotinine compositions
AU2008224844B2 (en) * 2007-03-14 2012-08-09 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
JP2010529142A (ja) * 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US9017301B2 (en) * 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
AU2008299220B2 (en) 2007-09-10 2011-07-21 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9775882B2 (en) * 2007-09-20 2017-10-03 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
EP2283160A4 (en) * 2008-05-07 2012-01-04 Wintherix Llc METHOD FOR IDENTIFYING WNT SIGNALING MODULATING COMPOUNDS IN CANCER CELLS
WO2009137631A2 (en) * 2008-05-07 2009-11-12 Wintherix Llc Methods for identifying compounds that affect expression of cancer-related protein isoforms
EP2363116A1 (en) * 2008-06-25 2011-09-07 US Worldmeds LLC Sustained-release formulations comprising lofexidine for oral delivery
WO2010005507A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
CA2734491A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
CA2734500A1 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US20100158905A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy of arthritis with tranilast
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
US20110009460A1 (en) * 2009-06-19 2011-01-13 Valentin Gribkoff Compositions and methods for treating amyotrophic lateral sclerosis
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
EP2534145A4 (en) 2010-02-08 2013-09-11 Kinagen Inc THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
CA2794086A1 (en) 2010-03-24 2011-09-29 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
EP2552448B1 (en) 2010-03-26 2019-04-24 Galderma Research & Development Improved compositions comprising brimonidine for safe and effective treatment of telangiectasia
DK2552449T3 (en) 2010-03-26 2017-06-19 Galderma Res & Dev COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM
DK2557924T3 (da) 2010-04-13 2019-09-23 Relmada Therapeutics Inc Dermale farmaceutiske sammensætninger af 1-methyl-2',6'-pipecoloxylidid og fremgangsmåde til deres anvendelse
US20130030237A1 (en) 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
HUE029570T2 (en) 2010-04-27 2017-03-28 Calcimedica Inc Intracellular calcium modifying compounds
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
BR112012027672A2 (pt) 2010-04-28 2023-12-05 Kimberly Clark Co Dispositivo médico compreendendo um conjunto de microagulhas que se estendem para fora a partir de um suporte e método para formar um dispositivo médico
RU2585159C2 (ru) 2010-04-28 2016-05-27 Кимберли-Кларк Ворлдвайд, Инк. Устройство доставки лекарственного средства, применяемого при ревматоидном артрите
RU2585138C2 (ru) 2010-04-28 2016-05-27 Кимберли-Кларк Ворлдвайд, Инк. Медицинские устройства для доставки кирнк
AU2011311255B2 (en) 2010-04-28 2015-10-08 Sorrento Therapeutics, Inc. Method for increasing permeability of an epithelial barrier
WO2011143152A2 (en) 2010-05-11 2011-11-17 Questcor Pharmaceuticals Acth for treatment of amyotrophic lateral sclerosis
US20120087915A1 (en) 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
MX354697B (es) 2010-10-21 2018-03-15 Galderma Sa Composiciones de gel de brimonidina y métodos de uso.
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
EP2636408B1 (en) * 2010-11-02 2018-04-25 Toyo Ink Sc Holdings Co., Ltd. Patch
CA3043905A1 (en) 2011-01-07 2012-07-12 Allergan, Inc. Compositions comprising substituted benzaldehydes and use thereof for lightening skin or treating hyperpigmenation and hypermelanosis disorders
CN103732611B (zh) 2011-01-10 2016-06-01 伊沃恩有限公司 β-肾上腺素能反向激动剂用于戒烟的用途
US8696637B2 (en) 2011-02-28 2014-04-15 Kimberly-Clark Worldwide Transdermal patch containing microneedles
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
WO2013061208A1 (en) 2011-10-27 2013-05-02 Kimberly-Clark Worldwide, Inc. Transdermal delivery of high viscosity bioactive agents
CA2795586A1 (en) 2011-11-15 2013-05-15 Golden Biotechnology Corporation Methods and compositions for treatment, modification and management of bone cancer pain
WO2013072763A2 (en) * 2011-11-16 2013-05-23 Nometics Inc. Non-sensitizing transdermal clonidine patch
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US20130172424A1 (en) 2011-12-30 2013-07-04 Golden Biotechnology Corporation Methods and compositions for treating diabetes
SE1350211A1 (sv) 2012-02-23 2013-08-24 Golden Biotechnology Corp Metoder och kompositioner för behandling av cancermetastaser
ES2886345T3 (es) 2012-03-26 2021-12-17 Golden Biotechnology Corp Métodos y composiciones para el tratamiento de enfermedades vasculares arterioescleróticas
EP3838293A1 (en) 2012-07-11 2021-06-23 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
WO2014051128A1 (ja) * 2012-09-28 2014-04-03 株式会社 ケイ・エム トランスダーム 貼付剤
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR102088078B1 (ko) 2012-11-21 2020-03-12 골든 바이오테크놀러지 코포레이션 신경퇴행성 질환을 치료하기 위한 방법 및 조성물
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
TWI597061B (zh) 2013-02-20 2017-09-01 國鼎生物科技股份有限公司 治療白血病之方法及組成物
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014153221A2 (en) 2013-03-14 2014-09-25 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
US9682068B2 (en) 2013-05-20 2017-06-20 Mylan Inc. Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
AU2014306683B2 (en) 2013-08-13 2017-10-12 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
EP3033081B1 (en) 2013-08-13 2021-05-12 Knopp Biosciences LLC Compositions and methods for treating chronic urticaria
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
CN106535889A (zh) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
EP3828160A1 (en) 2014-07-16 2021-06-02 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2016025329A1 (en) 2014-08-15 2016-02-18 Tepha, Inc. Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US10485893B2 (en) 2014-11-13 2019-11-26 Sarasota Medical Products, Inc. Antimicrobial hydrocolloid dressing containing sequestered peroxide and preparation thereof
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
CA2969429C (en) 2014-12-11 2020-10-27 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
CN107530304A (zh) 2015-02-27 2018-01-02 科泰纳制药公司 Olig2活性的抑制
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
EP3297645A4 (en) 2015-05-20 2018-12-12 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
HK1257338A1 (zh) 2015-08-31 2019-10-18 Pharmacyclics Llc 用於治疗多发性骨髓瘤的btk抑制剂组合
CN108883308A (zh) 2016-01-26 2018-11-23 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CA3024556A1 (en) 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
CN115215807A (zh) 2016-08-26 2022-10-21 科泰纳制药公司 Olig2活性的抑制
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
CA3037746A1 (en) 2016-10-07 2018-04-12 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US20190290597A1 (en) 2016-12-05 2019-09-26 Corsair Pharma, Inc. Dermal and transdermal administration of treprostinil and salts thereof
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
US11324729B2 (en) 2017-12-07 2022-05-10 The Regents Of The University Of Michigan NSD family inhibitors and methods of treatment therewith
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
JP2021527064A (ja) 2018-06-07 2021-10-11 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｐｒｃ１阻害剤及びそれを用いた治療方法
KR20210073513A (ko) 2018-07-27 2021-06-18 컨센트릭 애널지식스, 인크. 페놀성 trpv1 작용제의 peg화된 프로드럭
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
SG11202109899VA (en) 2019-03-15 2021-10-28 Unicycive Therapeutics Inc Nicorandil derivatives
CN111035627A (zh) * 2020-01-09 2020-04-21 范小玲 一种可乐定透皮贴及其制备方法
CA3168432A1 (en) 2020-05-08 2021-11-11 Golden Biotechnology Corporation Methods and compositions for treating an rna virus induced disease
JP7758369B2 (ja) 2020-07-10 2025-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｇａｓ４１阻害剤及びその使用方法
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
JP7138685B2 (ja) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
EP4384179A1 (en) 2021-08-11 2024-06-19 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
EP4370506A1 (en) 2021-12-30 2024-05-22 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
GB2618810A (en) 2022-05-17 2023-11-22 Novumgen Ltd Pharmaceutical composition for sublingual administration of clonidine
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20250145571A1 (en) 2023-09-26 2025-05-08 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025101867A1 (en) 2023-11-10 2025-05-15 Albert Einstein College Of Medicine Cell-impermeable akt inhibitors and pdpk1 inhibitors
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives
WO2025208111A1 (en) 2024-03-29 2025-10-02 Biomea Fusion, Inc. Heterocyclic glp-1r agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2143564A1 (en) * 1969-04-01 1973-02-09 Alza Corp Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates
FR2299853A1 (fr) * 1975-02-06 1976-09-03 Alza Corp Bandage therapeutique pour l'administration de scopolamine par voie percutanee

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products
US3190802A (en) * 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
DE1928798C3 (de) * 1969-06-06 1981-06-11 C.H. Boehringer Sohn, 6507 Ingelheim Verwendung von 2-(2,6-Dichlorphenylamino)-1,3-diazacyclopenten-(2)
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2143564A1 (en) * 1969-04-01 1973-02-09 Alza Corp Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates
FR2299853A1 (fr) * 1975-02-06 1976-09-03 Alza Corp Bandage therapeutique pour l'administration de scopolamine par voie percutanee

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0020905A1 (de) * 1979-05-21 1981-01-07 C.H. Boehringer Sohn Pharmazeutische Zubereitung in Form eines Polyacrylatfilmes und deren Herstellung
EP0232580A3 (en) * 1986-01-13 1989-06-21 Alza Corporation Transdermal system ii
EP0267051A3 (en) * 1986-11-07 1990-10-03 Moleculon Inc. Transdermal administration of amines
EP0345884A3 (en) * 1988-06-06 1990-12-05 The Dow Chemical Company Coextruded synthetic resin structures and a process for their manufacture
WO1997004818A3 (de) * 1995-07-29 1997-03-13 Lohmann Therapie Syst Lts Transdermales therapeutisches system zur abgabe von wirkstoffen über die haut an den menschlichen körper
US6074665A (en) * 1995-07-29 2000-06-13 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system for administering active agents to the human body via the skin

Also Published As

Publication number Publication date
DD135566A5 (de) 1979-05-16
IL52839A0 (en) 1977-10-31
IE46069B1 (en) 1983-02-09
PT67128A (fr) 1977-11-01
PL113984B1 (en) 1981-01-31
ZA775848B (en) 1978-08-30
JPS6214526B2 (cg-RX-API-DMAC10.html) 1987-04-02
BG29866A3 (bg) 1981-02-16
NO772955L (no) 1979-01-15
BE862585A (fr) 1978-05-02
CA1089362A (en) 1980-11-11
SU1005650A3 (ru) 1983-03-15
ATA905877A (de) 1980-11-15
AT362884B (de) 1981-06-25
HU179397B (en) 1982-10-28
DK159375C (da) 1991-03-18
AU512328B2 (en) 1980-10-02
YU166578A (en) 1985-03-20
YU41594B (en) 1987-10-31
FI772754A7 (fi) 1979-01-13
PT67128B (fr) 1979-03-16
ES245891U (es) 1980-06-01
JPS5420129A (en) 1979-02-15
DK159375B (da) 1990-10-08
DK387777A (da) 1979-01-13
PH16059A (en) 1983-06-09
SE7709731L (sv) 1979-01-13
NZ185000A (en) 1979-08-31
DE2755661A1 (de) 1979-01-25
AR218037A1 (es) 1980-05-15
NL7710213A (nl) 1979-01-16
LU78845A1 (fr) 1979-09-06
AU2846277A (en) 1979-03-08
FR2397190B1 (cg-RX-API-DMAC10.html) 1982-10-15
GR61591B (en) 1978-12-02
IL52839A (en) 1979-09-30
DE2755661C2 (de) 1986-05-22
US4201211A (en) 1980-05-06
GB1577259A (en) 1980-10-22
NL189800C (nl) 1993-08-02
ES245891Y (es) 1980-12-16
ES472073A1 (es) 1979-03-16
IT1104643B (it) 1985-10-21
IE46069L (en) 1979-01-12
PL204853A1 (pl) 1979-09-10
RO75336A (ro) 1980-12-30
CS216917B2 (en) 1982-12-31
CH646876A5 (de) 1984-12-28
NL189800B (nl) 1993-03-01

Similar Documents

Publication Publication Date Title
FR2397190A1 (fr) Moyen pour l'administration de medicaments a travers la peau
SE8703034D0 (sv) Oralt terapeutiskt system med systemisk verkan
DK662887A (da) Fladeformigt terapeutisk system, fremgangsmaade til fremstilling deraf og anvendelse deraf
KR910009264A (ko) 2-아미노-6-n-프로필아미노-4,5,6,7-테트라하이드로벤조티아졸의 경피 투여
DE3161605D1 (en) Therapeutic system for administering drugs to the skin
DE59009495D1 (de) Oestrogenhaltiges Wirkstoffpflaster.
ATE252350T1 (de) Gerät zum behandeln von herzstillständen
DK581685A (da) Transderimalt system for timolol-indgift
DK0861659T3 (da) Indretninger til administration af lægemidler med forsinket frigivelse
ATE188866T1 (de) Transdermales arzneimittelverabreichungssystem
ES2018270B3 (es) Dispositivo de liberacion controlado para una sustancia activa.
SE8600947L (sv) Farmaceutiska beredningar och forfarande for behandling av minnesrubbningar
DE3879853D1 (de) Klebstoffzusammensetzung, zusammensetzung mit kontrollierter wirkstofffreisetzung und system zur transdermalen anwendung von arzneien.
LV10047A (lv) Medetomidina saju un to optiski aktivo enantiomeru izmantosana medicinisko preperatu transdermalas iedarbibas pakapes regulesanai
AU622775B2 (en) A plaster used as therapeutic system for the administration of active substances to the skin, which exhibits a graduated active substance release, process for the production of the plaster and the use thereof
ATE63059T1 (de) Vorrichtung mit zwei schichten zur freisetzung von arzneimitteln.
YU49390A (sh) Postupak za izradu transdermalnog terapijskog sistema sa stupnjevitim otpuštanjem aktivne materije
DE3485306D1 (de) Pharmazeutische zusammensetzung mit verzoegerter abgabe und verfahren zu deren herstellung.
GB1361289A (en) Bandage for administering drugs
ATE89756T1 (de) Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen.
JPS577413A (en) Plaster
JPS56100716A (en) Drug administration member
FI952269A0 (fi) Ihonläpäisevä terapeuttinen järjestelmä fysostigmiinin antamiseen iholle ja menetelmä järjestelmän valmistamiseksi
NO881870L (no) Doseringsenhet for transdermal absorbsjon av narkotiske analgetiske og antagonistiske stoffer og fremgangsmaate for administrering av samme.
IT8144004A0 (it) Dispositivo atto a controllare la regolare erogazione di soluzione somministrata al paziente mediante fleboclisi e a segnalare ogni possibile inconveniente